07.09.2016 • NewsElaine BurridgeArkemaelectronics

Arkema Hikes Specialty Polyamides Capacities

Arkema is expanding capacity for specialty polyamides in China and the US to support its customers’ growth around the world, particularly in the sports, consumer electronics and automotive markets. At its Zhangjiagang site in Jiangsu province, China, the French chemical producer is increasing its compounding capacities and will bring on stream two production lines for polyamide 11 in 2017, adding to the polyamide 10 already produced there. Arkema said this and other investments made in recent years at Zhangjiagang amount to €10 million overall.

In the US, an investment at Birdsboro, Pennsylvania, will enable the manufacture of Arkema’s new Pebax biosourced grades for the sports and electronics markets. The company said the projects are part of its research and growth platforms centered on weight reduction, material design, solutions for electronics, and the development of biosourced products.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.